Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-19-059173
Filing Date
2019-11-04
Accepted
2019-11-04 06:05:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a19-21684_2sc13da.htm SC 13D/A 46464
2 EX-7.05 a19-21684_2ex7d05.htm EX-7.05 1173179
  Complete submission text file 0001104659-19-059173.txt   1221155
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filed by) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SC 13D/A

Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Subject) CIK: 0001740547 (see all company filings)

EIN.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SC 13D/A | Act: 34 | File No.: 005-90671 | Film No.: 191188175
SIC: 2834 Pharmaceutical Preparations